TuHURA Biosciences AI Stock Analysis
Want to see HURA full AI Analyst Report?
TuHURA Biosciences (HURA) AI Stock Analysis
TuHURA Biosciences
(NASDAQ:HURA)
The score is primarily held back by weak financial performance (no revenue, large recurring losses, and persistent negative free cash flow). Technicals also point to a bearish trend with the stock below key moving averages and negative MACD. Corporate events provide some liquidity and operational flexibility but also highlight continued dependence on financing and potential dilution, while valuation inputs are limited due to negative earnings and no dividend yield provided.
TuHURA Biosciences (HURA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $89.43M
- Dividend Yield
- ―
- Average Volume (3M)
- 327.31K
- Price to Earnings (P/E)
- -2.7
- Beta (1Y)
- 1.81
- Revenue Growth
- ―
- EPS Growth
- 24.26%
- Country
- US
- Employees
- 22
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
TuHURA Biosciences Business Overview & Revenue Model
Company Description
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by whic...
TuHURA Biosciences Financial Statement Overview
Summary
Overall fundamentals are weak: the company reports no revenue and persistent sizable net losses (about ~$29.9M in TTM) alongside consistently negative free cash flow (about -$23.8M in TTM), indicating ongoing cash burn and reliance on external funding. The main offset is a relatively conservative balance sheet in recent periods with low leverage (debt-to-equity roughly ~0.01–0.02) and positive equity, which reduces near-term leverage risk.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -23.47K | 0 | 0 | -55.00K | -60.00K | -60.00K |
| EBITDA | -27.97M | -29.36M | -17.43M | -8.14M | -14.28M | -21.65M |
| Net Income | -29.94M | -30.06M | -21.68M | -8.32M | -14.65M | -22.66M |
Balance Sheet | ||||||
| Total Assets | 36.24M | 27.35M | 19.97M | 4.36M | 15.20M | 6.40M |
| Cash, Cash Equivalents and Short-Term Investments | 1.89M | 3.62M | 12.66M | 3.67M | 14.25M | 5.55M |
| Total Debt | 9.56M | 700.02K | 202.54K | 2.34M | 138.22K | 644.07K |
| Total Liabilities | 17.29M | 6.42M | 5.37M | 5.92M | 2.89M | 7.15M |
| Stockholders Equity | 18.95M | 20.93M | 14.59M | -1.56M | 12.30M | -747.82K |
Cash Flow | ||||||
| Free Cash Flow | -23.82M | -27.71M | -14.79M | -12.03M | -7.54M | -6.57M |
| Operating Cash Flow | -23.61M | -27.63M | -14.73M | -11.95M | -7.51M | -6.56M |
| Investing Cash Flow | -213.67K | -1.34M | -6.05M | -1.30M | -36.28K | -3,280 |
| Financing Cash Flow | 23.02M | 19.93M | 29.77M | 2.66M | 16.25M | 7.04M |
TuHURA Biosciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HURA, the sentiment is Negative. The current price of 1.36 is below the 20-day moving average (MA) of 1.71, below the 50-day MA of 1.88, and below the 200-day MA of 2.03, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 33.51 is Neutral, neither overbought nor oversold. The STOCH value of 19.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HURA.
TuHURA Biosciences Risk Analysis
TuHURA Biosciences disclosed 62 risk factors in its most recent earnings report. TuHURA Biosciences reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksTuHURA Biosciences Peers Comparison
Overall Rating
AGEN57Neutral
INO55Neutral
CGTX45Neutral
HURA45Neutral
BMEA42Neutral
SKYE42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 57Neutral | $277.81M | 8.35 | -15.48% | ― | 25.38% | ― | |
| 55Neutral | $320.29M | -2.15 | -9999.00% | ― | 63.93% | 68.94% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $57.12M | -3.56 | -50.57% | ― | ― | 62.99% | |
| 45Neutral | $89.43M | -2.72 | -146.80% | ― | ― | 24.26% | |
| 42Neutral | $42.76M | -1.86 | -131.27% | ― | ― | 87.11% | |
| 42Neutral | $3.48M | -0.10 | -503.95% | ― | ― | 26.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HURA | Tuhura Biosciences, Inc. | 1.36 | -0.38 | -21.84% | |
| AGEN | Agenus Inc. | 6.14 | 1.92 | 45.50% | |
| INO | Inovio Pharmaceuticals | 1.71 | -0.05 | -2.84% | |
| SKYE | Skye Bioscience, Inc. | 0.79 | -8.53 | -91.57% | |
| BMEA | Biomea Fusion Inc | 0.59 | -0.39 | -40.00% | |
| CGTX | Cognition Therapeutics, Inc. | 0.60 | -0.79 | -56.83% |
TuHURA Biosciences Corporate Events
TuHURA Biosciences Borrows Additional Funds Under Credit Facility
NeutralTuHURA Biosciences had entered a revolving credit facility with Parkview Holdings One LLC on April 21, 2026. On November 2, 2026, it borrowed an additional $1.5 million under the facility, which allows up to $50 million and matures April 21, 2031. Th...
TuHURA Biosciences Adds Borrowing Under Credit Facility
NeutralOn April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC for a revolving credit facility of up to $50 million, maturing on April 21, 2031. This long-term financing arrangement provides the company with...
TuHURA Biosciences Draws Additional Funds From Credit Facility
NeutralTuHURA Biosciences, Inc. entered into a revolving credit facility loan agreement with Parkview Holdings One LLC on April 21, 2026, providing up to $50 million in borrowing capacity and maturing on April 21, 2031. The arrangement underscores the compa...
TuHURA Biosciences Expands Use of Revolving Credit Facility
NeutralTuHURA Biosciences, Inc. operates in the biotechnology and life sciences sector and is focused on developing medical and biopharmaceutical innovations. The company accesses external financing through structured credit facilities to support its operat...
TuHURA Biosciences Adopts 2026 Inducement Equity Plan
PositiveOn September 10, 2026, TuHURA Biosciences’ board adopted a 2026 Inducement Equity Incentive Plan designed to grant equity awards to new employees as a material inducement to join the company or its subsidiaries. The plan reserves 5,000,000 shares of...
TuHURA Biosciences draws additional funds from credit facility
PositiveTuHURA Biosciences, Inc. previously entered into a revolving credit facility with Parkview Holdings One LLC on April 21, 2026, providing up to $50 million in loan availability and maturing on April 21, 2031. On September 2, 2026, the company drew an...
TuHURA Biosciences Expands Use of Revolving Credit Facility
PositiveOn April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC establishing a revolving credit facility of up to $50 million that matures on April 21, 2031. On August 20, 2026, the company drew an additional...
TuHURA Biosciences Reports Results of 2026 Annual Meeting
PositiveOn August 18, 2026, TuHURA Biosciences held its 2026 Annual Meeting, where a quorum of stockholders representing 43 million shares participated in key governance decisions. Shareholders elected six directors to serve until the 2027 Annual Meeting, ap...
TuHURA Biosciences Expands Use of Revolving Credit Facility
PositiveOn April 21, 2026, TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC for a revolving credit facility of up to $50 million, maturing on April 21, 2031. The agreement provides the company with flexible access to capi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
